Physician profile
Traci Beck
NPI 1710963749
$32,364.98
in general payments reported to CMS, 2019-2025
25 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,591 · 2021: $7,853 · 2022: $7,860 · 2023: $379 · 2024: $1,946 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151 · Travel and Lodging: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.68 |
| Travel and Lodging | $656.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17,430.26 | 2019-2021 | |
| Urovant Sciences INC | $9,675.89 | 2021-2022 | |
| Boston Scientific Corporation | $1,668.57 | 2019-2025 | Solyx Sis System, Bulkamid, Advantage System |
| Axonics, INC. | $1,335.04 | 2023-2024 | Axonics, Bulkamid |
| Abbvie INC. | $410.56 | 2019-2025 | |
| Medtronic, INC. | $319.02 | 2022-2024 | Interstim |
| Allergan, INC. | $267.53 | 2019-2022 | |
| Bluewind Medical | $263.24 | 2024 | Revi |
| Femselect INC. | $171.12 | 2024-2025 | Enplace |
| Laborie Medical Technologies Corp. | $124.99 | 2019 | |
| Novo Nordisk INC | $121.93 | 2019 | |
| Medtronic USA, INC. | $104.38 | 2019 | |
| Olympus America INC. | $99.29 | 2022 | |
| Acessa Health INC. | $74.66 | 2019 | |
| Astellas Pharma Global Development | $62.65 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $36.85 | 2022 | |
| Sumitomo Pharma America, INC. | $33.53 | 2025 | Myfembree |
| Gilead Sciences, INC. | $26.34 | 2023 | Vemlidy |
| Fresenius Kabi USA, LLC | $23.67 | 2023 | Idacio |
| Gynesonics, INC. | $23.25 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exact Sciences Corporation | $22.26 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $18.78 | 2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Pfizer INC. | $18.71 | 2019 | |
| Amgen INC. | $17.47 | 2023 | Prolia, Evenity |
| Minerva Surgical, INC | $14.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.